Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Purpose:
To develop a real time national clinical database to support and share best practices,
Each patient visit will include the following observational endpoints:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Dermatologic patients in Canada for which Amevive is clinically indicated |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Understand how AMEVIVE is used in routine clinical practice/real world setting | End of study |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Dermatologic patients in Canada
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Use Central Contact | Astellas Pharma Canada, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Calgary | Alberta | T2S 3B3 | Canada | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20053322 | Background | Searles G, Bissonnette R, Landells I, Shear NH. Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S107-12. doi: 10.2310/7750.2009.00028. No abstract available. | |
| 20053323 | Background | Bissonnette R, Searles G, Landells I, Shear NH, Papp K, Lui H, Gulliver WP, Lynde C. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S113-21. doi: 10.2310/7750.2009.00029. |
| Label | URL |
|---|---|
| Link to FDA Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Calgary |
| Alberta |
| T3A 2N1 |
| Canada |
| Edmonton | Alberta | T5J 3S9 | Canada |
| Edmonton | Alberta | T5K 1X3 | Canada |
| Surrey | British Columbia | V3R6A7 | Canada |
| Vancouver | British Columbia | V5Z 3Y1 | Canada |
| Vancouver | British Columbia | V5Z 4E8 | Canada |
| Victoria | British Columbia | V8V 3P9 | Canada |
| Victoria | British Columbia | V8V 4X3 | Canada |
| Winnipeg | Manitoba | R3C 1R4 | Canada |
| Moncton | New Brunswick | E1C 8X3 | Canada |
| Saint John | New Brunswick | E2M 3W5 | Canada |
| St. John's | Newfoundland and Labrador | A1B 3A1 | Canada |
| St. John's | Newfoundland and Labrador | A1B 3E1 | Canada |
| St. John's | Newfoundland and Labrador | A1B 4S8 | Canada |
| Halifax | Nova Scotia | B3H 124 | Canada |
| Barrie | Ontario | L7M 6L7 | Canada |
| Concord | Ontario | L4K 5V2 | Canada |
| Hamilton | Ontario | L8N 3H7 | Canada |
| London | Ontario | N6A 3H7 | Canada |
| London | Ontario | N6H 1S9 | Canada |
| Markham | Ontario | L3P 1A8 | Canada |
| Oakville | Ontario | L6K 1E1 | Canada |
| Toronto | Ontario | M5S 1B6 | Canada |
| Waterloo | Ontario | N2J 1C4 | Canada |
| Windsor | Ontario | N8W 5L7 | Canada |
| Montreal | Quebec | H2K 4L5 | Canada |
| Montreal | Quebec | H3G 1A1 | Canada |
| Québec | Quebec | G1J 1X7 | Canada |
| Sainte-Foy | Quebec | G1V 4X7 | Canada |
| 20053324 | Background | Landells I, Searles G, Bissonnette R, Shear NH, Vender R, Lui H. Efficacy outcomes in patients using alefacept in the AWARE study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S122-30. doi: 10.2310/7750.2009.00030. |
| 20053325 | Background | Searles G, Bissonnette R, Landells I, Shear NH, Papp K, Lui H. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S131-8. doi: 10.2310/7750.2009.00031. |
| 20053326 | Background | Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP. Update on alefacept safety. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S139-47. doi: 10.2310/7750.2009.00032. |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided